Renal Cell Carcinoma (RCC) – Reviews and Forecast - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Renal Cell Carcinoma (RCC) – Reviews and Forecast

Description:

Renal cell carcinoma (RCC) is a sort of kidney disease that begins in the coating of the proximal convoluted tubule, a part of the little tubes in the kidney that vehicle waste particles from the blood to the pee. RCC is the most widely recognized kind of kidney growth in grown-ups, being in charge of roughly 90% of all cases in grown-ups. The condition is asymptomatic in its underlying stages, and accordingly, individuals with RCC are frequently in the propelled phases of the sickness when it is found. The underlying manifestations of RCC regularly incorporate blood in the pee, flank torment, a mass in the belly or flank, weight reduction, fever, hypertension, night sweats, and a general sentiment being unwell. Kidney disease is among the 10 most every now and again happening malignancies in Western nations. Universally, around 270,000 instances of kidney tumor are analyzed yearly, and 116,000 individuals kick the bucket from the illness. – PowerPoint PPT presentation

Number of Views:45

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Renal Cell Carcinoma (RCC) – Reviews and Forecast


1
EpiCast Report Renal Cell Carcinoma -
Epidemiology Forecast to 2023
Telephone 1 (800) 910-6452Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview
  • Renal cell carcinoma (RCC) is a type of kidney
    cancer that originates in the lining of the
    proximal convoluted tubule, a part of the very
    small tubes in the kidney that transport waste
    molecules from the blood to the urine. RCC is the
    most common type of kidney cancer in adults,
    being responsible for approximately 90 of all
    cases in adults. The condition is asymptomatic in
    its initial stages, and as a result, people with
    RCC are often in the advanced stages of the
    disease by the time it is discovered. The initial
    symptoms of RCC often include blood in the urine,
    flank pain, a mass in the abdomen or flank,
    weight loss, fever, hypertension, night sweats,
    and a general feeling of being unwell. Kidney
    cancer is among the 10 most frequently occurring
    cancers in Western countries. Globally, about
    270,000 cases of kidney cancer are diagnosed
    yearly, and 116,000 people die from the disease.
  • The epidemiologists forecast an increase in the
    diagnosed incident cases of RCC in the 8MM, from
    190,147 diagnosed incident cases in 2013 to
    309,734 diagnosed incident cases in 2023, with an
    Annual Growth Rate (AGR) of 6.29 during the
    forecast period. In 2023, urban China will have
    the highest number of diagnosed incident cases of
    RCC in the 8MM, with 147,457 diagnosed incident
    cases, whereas Spain will have the lowest number
    of diagnosed incident cases of RCC, with 7,591
    diagnosed incident cases. Similarly, as shown in
    the second figure below, the five-year diagnosed
    prevalent cases of RCC in the 8MM will increase
    from 600,261 diagnosed prevalent cases in 2013 to
    966,190 diagnosed prevalent cases in 2023, with
    an AGR of 6.10 during the forecast period. The
    increase in the diagnosed five-year prevalent
    cases of RCC is partly attributed to the rising
    trend in the incidence rate of RCC in the 8MM,
    combined with changes in the population
    demographics in the respective markets. The
    rising trend in the incidence of RCC may partly
    be a result of increased use of imaging
    techniques that can detect asymptomatic tumors.

3


Report Overview
  • Scope
  • - The Renal cell carcinoma (RCC) EpiCast Report
    provides an overview of the risk factors,
    comorbidities, and the global and historical
    trends for RCC in the eight major markets (8MM)
    (US, France, Germany, Italy, Spain, UK, Japan,
    and urban China). It includes a 10-year
    epidemiological forecast for the diagnosed
    incident cases of RCC, segmented by age (at
    20-year intervals, starting at age 20 years and
    ending at ages 80 years) and sex. It also
    includes a forecast of the five-year diagnosed
    prevalent cases of RCC in the 8MM. Additionally,
    it provides the RCC diagnosed incident cases,
    segmented by the stage at diagnosis, for the 8MM.
  • The RCC epidemiology report is written and
    developed by Masters- and PhD-level
    epidemiologists.
  • The EpiCast Report is in-depth, high quality,
    transparent and market-driven, providing expert
    analysis of disease trends in the 8MM.
  • Reasons to buy
  • The RCC EpiCast report will allow you to -
  • - Develop business strategies by understanding
    the trends shaping and driving the global RCC
    market.
  • - Quantify patient populations in the global RCC
    market to improve product design, pricing, and
    launch plans.
  • - Organize sales and marketing efforts by
    identifying the age groups and sex that present
    the best opportunities for RCC therapeutics in
    each of the markets covered.

4


Table of Contents
1 Table of Contents 4 1.1 List of Tables 6 1.2
List of Figures 7 2 Introduction 8 2.1 Catalyst
8 2.2 Upcoming Related Reports 8 3 Epidemiology
9 3.1 Disease Background 9 3.2 Risk Factors and
Comorbidities 10 3.3 Global Trends 12 3.3.1
Incidence 12 3.3.2 Survival Rates for RCC - 8MM
14 3.4 Forecast Methodology 15 3.4.1 Sources Used
17 3.4.2 Sources Not Used 20 3.4.3 Forecast
Assumptions and Methods, RCC Diagnosed Incident
Cases 21 3.5 Epidemiological Forecast for RCC
(2013-2023) 23 3.5.1 Diagnosed Incident Cases of
RCC 23 3.5.2 Age-Specific Diagnosed Incident
Cases of RCC 25 3.5.3 Sex-Specific Diagnosed
Incident Cases of RCC 27 3.6 Discussion 33 3.6.1
Epidemiological Forecast Insight 33 4 Appendix 36
5


Report Ordering
Report Name EpiCast Report Renal
Cell Carcinoma - Epidemiology Forecast to
2023
Product Price
User Price
Single User US 3396
Site User US 7990
Global User US 11985
To View Sample or Purchase Report
6



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/epicast-report-renal-c
ell-carcinoma-epidemiology-forecast-to-2023-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com
About PowerShow.com